STA
ALNY icon

Summit Trail Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Summit Trail Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Sell
3,526
-72
-2% -$21.7K 0.01% 967
2026
Q1 		$1.19M Buy
3,598
+84
+2% +$28.6K 0.02% 857
2025
Q4 		$1.4M Buy
3,514
+79
+2% +$35K 0.02% 635
2025
Q3 		$1.57M Buy
3,435
+626
+22% +$255K 0.02% 579
2025
Q2 		$916K Buy
2,809
+1,006
+56% +$278K 0.02% 510
2025
Q1 		$487K Buy
1,803
+518
+40% +$133K 0.02% 256
2024
Q4 		$302K Buy
1,285
+151
+13% +$39.7K 0.01% 289
2024
Q3 		$312K Buy
1,134
+205
+22% +$53.4K 0.01% 533
2024
Q2 		$226K Buy
+929
New +$147K 0.01% 560
2018
Q1 		– Sell
-289
Closed -$39K – 467
2017
Q4 		$39K Buy
+289
New +$36.3K ﹤0.01% 884

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Trail Advisors's ALNY Position: Q2 2026 in Review

Summit Trail Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 2% in Q2 2026, selling an estimated $21.7K and leaving 3,526 shares worth $1.06M. The position accounts for 0.01% of the portfolio, ranked #967.

Summit Trail Advisors first reported a position in ALNY in Q4 2017 and has held it in 10 quarters since. The position peaked at $1.57M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Summit Trail Advisors held 3,526 shares of Alnylam Pharmaceuticals worth $1.06M as of Q2 2026.
  • Summit Trail Advisors sold 72 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $21.7K.
  • Alnylam Pharmaceuticals made up 0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #967 holding.
  • Summit Trail Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2017 and has held it in 10 quarters since.
  • Summit Trail Advisors's Alnylam Pharmaceuticals position peaked at $1.57M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.